

David Jayne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11960928/publications.pdf>

Version: 2024-02-01

161
papers

20,824
citations

19657

61
h-index

10158

140
g-index

165
all docs

165
docs citations

165
times ranked

10603
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
2	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	5.6	50
3	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	5.6	71
4	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	5.6	62
5	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. <i>European Journal of Internal Medicine</i> , 2022, 99, 19-21.	2.2	4
6	Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE). <i>Arthritis Research and Therapy</i> , 2022, 24, 81.	3.5	12
7	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152021.	3.4	2
8	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1769-1772.	0.9	9
9	Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , 2021, 60, 2745-2754.	1.9	30
10	Increasing incidence and improved survival in ANCA-associated vasculitis—a Danish nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 63-71.	0.7	21
11	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021, 60, 4355-4360.	1.9	21
12	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , 2021, 60, 359-365.	1.9	27
13	Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. <i>Rheumatology</i> , 2021, 60, 4538-4547.	1.9	13
14	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
15	Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?. <i>Journal of Rheumatology</i> , 2021, 48, 479-481.	2.0	1
16	ANCA-Associated Vasculitis: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 1446.	2.4	70
17	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	2
18	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Understanding tubulointerstitial injury and repair mechanisms paves the way for renal outcome improvement in lupus nephritis. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 82-89.	0.1	1
20	Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1673-1682.	5.6	17
21	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1134-1138.	3.4	4
22	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
23	Response to: "Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine" by Novikov et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e20-e20.	0.9	2
24	Response to: "Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al" by Vanderghenst et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e101-e101.	0.9	0
25	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	5.8	79
26	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. <i>RMD Open</i> , 2020, 6, e001263.	3.8	39
27	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
28	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	3.4	17
29	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.9	463
30	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
31	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	5.6	36
32	Le Relapsing Polychondritis Damage Index (RPDAM): développement d'un score clinique au cours de la polychondrite atrophiante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 122-127.	0.0	0
33	Prognosis and Outcomes of ANCA-Associated Vasculitis. <i>Rare Diseases of the Immune System</i> , 2020, , 293-311.	0.1	0
34	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 301-308.	0.7	20
35	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2019, 58, 260-268.	1.9	40
36	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , 2019, 14, 1193-1197.	2.0	13

#	ARTICLE	IF	CITATIONS
37	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
38	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
39	ANCA associated vasculitis: The journey to complement-targeted therapies. <i>Molecular Immunology</i> , 2019, 112, 394-398.	2.2	23
40	Complement inhibition in ANCA vasculitis. <i>Nephrologie Et Therapeutique</i> , 2019, 15, 409-412.	0.5	21
41	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.9	51
42	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	5.6	82
43	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	2.9	82
44	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , 2019, 5, e000905.	3.8	66
45	Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. <i>Rheumatology</i> , 2019, 58, 1707-1709.	1.9	32
46	Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. <i>Lupus Science and Medicine</i> , 2019, 6, e000308.	2.7	8
47	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 37-42.	1.2	9
48	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.9	1,265
49	Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. <i>Lupus Science and Medicine</i> , 2019, 6, e000337.	2.7	4
50	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	1.6	8
51	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	2.0	45
52	Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 784-791.	5.6	15
53	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.9	165
54	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 63-73.	0.7	96

#	ARTICLE	IF	CITATIONS
55	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	6.1	39
56	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018, 57, 14-18.	1.9	43
57	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	1.9	73
58	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	1.9	247
59	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581.	3.4	91
60	Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). <i>Arthritis and Rheumatology</i> , 2018, 70, 109-114.	5.6	71
61	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.8	41
62	B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. <i>Nature Reviews Rheumatology</i> , 2018, 14, 580-591.	8.0	61
63	End-stage renal disease in ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw046.	0.7	51
64	Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Rheumatology</i> , 2017, 56, kew465.	1.9	24
65	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
66	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.	27.0	682
67	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.9	159
68	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017, 19, 129.	3.5	42
69	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.8	21
70	Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	8.0	302
71	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 951-962.	3.0	29
72	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	3.3	44

#	ARTICLE	IF	CITATIONS
73	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	5.8	140
74	Long-term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). <i>Arthritis Care and Research</i> , 2016, 68, 374-387.	3.4	82
75	Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 713-723.	5.6	42
76	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>European Respiratory Journal</i> , 2016, 48, 1429-1441.	6.7	102
77	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339.	0.8	1
78	Clinical Trials in Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 161-177.	1.4	7
79	Sustained remission in lupus nephritis: still a hard road ahead. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2011-2018.	0.7	14
80	Outcome assessment in Takayasu arteritis. <i>Rheumatology</i> , 2016, 55, 1159-1171.	1.9	26
81	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015, 66, 613-620.	1.9	52
82	Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 814-821.	0.7	85
83	Lupus nephropathy and vasculitis. <i>Medicine</i> , 2015, 43, 538-544.	0.4	2
84	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	2.2	371
85	Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, i1-i7.	0.7	17
86	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	1.9	104
87	New Biologics for Glomerular Disease on the Horizon. <i>Nephron Clinical Practice</i> , 2015, 128, 283-291.	2.3	6
88	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.9	214
89	Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. <i>Journal of Nephrology</i> , 2015, 28, 17-27.	2.0	20
90	Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan. <i>Journal of Rheumatology</i> , 2014, 41, 325-333.	2.0	83

#	ARTICLE	IF	CITATIONS
91	Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 1-6.	4.3	17
92	ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1764-1769.	0.7	99
93	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
94	Extending the Indications for Rituximab in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1839-1840.	27.0	1
95	Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 73.	1.6	198
96	Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-blind, Phase III Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2368-2379.	6.7	272
97	New-generation therapy for ANCA-associated vasculitis. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 694-696.	1.6	7
98	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , 2013, 15, S2.	3.5	109
99	Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener's). <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 345-354.	1.6	33
100	S2. Rituximab for ANCA-associated vasculitis: The UK experience. <i>Presse Medicale</i> , 2013, 42, 532-534.	1.9	4
101	L27. Antibodies versus phenotypes: A clinician's view. <i>Presse Medicale</i> , 2013, 42, 579-582.	1.9	5
102	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 844-844.	6.7	1
103	A disease activity score for ENT involvement in granulomatosis with polyangiitis (Wegener's). <i>Laryngoscope</i> , 2013, 123, 622-628.	2.0	13
104	Current modalities in the diagnosis of pulmonary vasculitis. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 499-516.	1.6	6
105	Diagnosis and management of ANCA associated vasculitis. <i>BMJ: British Medical Journal</i> , 2012, 344, e26-e26.	2.3	100
106	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	5.8	71
107	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
108	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.9	348

#	ARTICLE	IF	CITATIONS
109	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012, 11, 357-364.	5.8	209
110	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 542-548.	6.7	298
111	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	6.4	182
112	Switching of anti-TNF- α agents in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S62-8.	0.8	42
113	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.9	47
114	Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2011, 365, 1886-1895.	27.0	544
115	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 488-494.	0.9	719
116	Lupus nephropathy and vasculitis. <i>Medicine</i> , 2011, 39, 486-491.	0.4	2
117	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011, 57, 566-574.	1.9	179
118	Long-term damage to the ENT system in Wegener's granulomatosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011, 268, 733-739.	1.6	17
119	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	3.4	147
120	Management of Alveolar Hemorrhage in Lung Vasculitides. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 335-345.	2.1	43
121	Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg's-Strauss syndrome and renal limited vasculitis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 12-17.	4.3	62
122	Mortality in Wegener's granulomatosis: a bimodal pattern. <i>Rheumatology</i> , 2011, 50, 697-702.	1.9	69
123	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2071-2074.	0.9	58
124	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. <i>Arthritis Care and Research</i> , 2010, 62, 1166-1173.	3.4	200
125	Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. <i>Rheumatology</i> , 2010, 49, 128-140.	1.9	290
126	Rituximab Treatment for Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1359-1362.	4.5	9

#	ARTICLE	IF	CITATIONS
127	Lupus Nephritis. , 2010, , 308-321.		4
128	Prospective study of TNF α blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrology Dialysis Transplantation, 2010, 25, 3307-3314.	0.7	81
129	The Pulmonary Vasculitides. Clinics in Chest Medicine, 2010, 31, 519-536.	2.1	21
130	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1036-1043.	0.9	344
131	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
132	Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1103-1112.	6.1	923
133	Assessment of damage in vasculitis: expert ratings of damage. Rheumatology, 2009, 48, 823-827.	1.9	34
134	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmunity Reviews, 2009, 9, 82-89.	5.8	62
135	Newer therapies for vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 379-389.	3.3	14
136	The diagnosis of vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 445-453.	3.3	76
137	Treatment of ANCA-associated systemic small-vessel vasculitis. Apmis, 2009, 117, 3-9.	2.0	12
138	Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology, 2009, 14, 42-48.	1.6	46
139	Development of comprehensive disease assessment in systemic vasculitis. Postgraduate Medical Journal, 2008, 84, 143-152.	1.8	91
140	Challenges in the management of microscopic polyangiitis: past, present and future. Current Opinion in Rheumatology, 2008, 20, 3-9.	4.3	39
141	Renal Vasculitis in the Elderly. , 2008, , 373-384.		0
142	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 569-570.	0.9	2
143	Chapter 8 ANCA-Associated Vasculitis: Clinical Features and Treatment. Handbook of Systemic Autoimmune Diseases, 2007, , 139-157.	0.1	1
144	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524

#	ARTICLE	IF	CITATIONS
145	Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 968-975.	4.5	119
146	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007, 57, 686-693.	6.7	243
147	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007, 34, 1357-71.	2.0	33
148	Antineutrophil Cytoplasmic Antibodies and the Churgâ€“Strauss Syndrome. <i>Annals of Internal Medicine</i> , 2005, 143, 632.	3.9	592
149	How to induce remission in primary systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 293-305.	3.3	21
150	Diagnosis and treatment of kidney disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 785-798.	3.3	26
151	Mycophenolate Mofetil for Remission Induction in Severe Lupus Nephritis. <i>Nephron Clinical Practice</i> , 2005, 100, c92-c100.	2.3	32
152	Autologous stem cell transplantation for systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 168-176.	1.6	169
153	Prospective Study of TNF± Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 717-721.	6.1	345
154	Predictors of outcome in renal vasculitis. <i>Nephrology</i> , 2004, 9, 254-255.	1.6	1
155	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. <i>New England Journal of Medicine</i> , 2003, 349, 36-44.	27.0	1,239
156	Current Attitudes to the Therapy of Vasculitis. <i>Kidney and Blood Pressure Research</i> , 2003, 26, 231-239.	2.0	34
157	Update on the European Vasculitis Study Group trials. <i>Current Opinion in Rheumatology</i> , 2001, 13, 48-55.	4.3	148
158	Clinical management and treatment of vasculitis. <i>Seminars in Immunopathology</i> , 2001, 23, 267-286.	4.0	7
159	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). <i>American Journal of Clinical Pathology</i> , 1999, 111, 507-513.	0.7	539
160	Non-transplant uses of mycophenolate mofetil. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 563-567.	2.0	40
161	Pulmonary-Renal Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1998, 19, 69-77.	2.1	11